Trillium Therapeutics Appoints Paolo Pucci to Its Board of Directors
November 12 2020 - 4:05PM
Trillium Therapeutics Inc.
(“Trillium” or the “Company”) (NASDAQ/TSX:
TRIL), a clinical stage immuno-oncology company developing
innovative therapies for the treatment of cancer, today announced
the appointment of pharmaceutical industry leader Paolo Pucci to
its Board of Directors, effective immediately. Mr. Pucci has
significant expertise in oncology drug development and decades of
leadership experience across large and small organizations over his
30 year career.
“We are delighted to welcome Mr. Pucci to the
board of directors” said Robert L. Kirkman, M.D., Chair of Trillium
Therapeutics. “His broad executive and commercial expertise,
specifically in the field of oncology, will be invaluable as
Trillium prepares for later stage clinical development.”
Most recently, Mr. Pucci served as Chief
Executive Officer of the targeted therapeutics oncology company,
ArQule, until it was acquired by Merck for $2.7 billion in January
2020. Prior to ArQule, Mr. Pucci served in a number of leadership
positions at Bayer AG from 2001 to 2008, including President of the
Oncology & Global Specialty Medicines Business Units and was a
member of the Bayer Pharmaceuticals Global Management Committee.
Mr. Pucci also held multiple roles at Eli Lily and Company from
1991 to 2001.
Mr. Pucci received his M.S. in economics and
accounting from Università degli Studi di Napoli Federico II and an
MBA in marketing and finance from the University of Chicago. He
currently serves as a board member of West Pharmaceuticals Services
Inc., Merus N.V. and Replimune Inc., and had previous board roles
at NewLink Genetics Inc., Dyax Inc. and Algeta ASA.
“I look forward to contributing my knowledge in
oncology drug development and commercialization over the coming
years,” said Mr. Pucci. “There has never been a more exciting time
to be developing novel oncology agents, and Trillium is well
positioned in the field.”
About Trillium
Therapeutics
Trillium is an immuno-oncology company
developing innovative therapies for the treatment of cancer. The
company’s two clinical programs, TTI-621 and TTI-622, target
CD47, a “don’t eat me” signal that cancer cells frequently use to
evade the immune system.
For more information visit:
www.trilliumtherapeutics.com
Investor
Relations:James ParsonsChief Financial
OfficerTrillium Therapeutics Inc. 416-595-0627
x232james@trilliumtherapeutics.com www.trilliumtherapeutics.com
Media Relations:Mike BeyerSam
Brown Inc.312-961-2502mikebeyer@sambrown.com
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Trillium Therapeutics (NASDAQ:TRIL)
Historical Stock Chart
From Sep 2023 to Sep 2024